Posts Tagged ‘Timothy Cannon’
“Should Runners Be Worried About Colon Cancer?,” Runner’s World, September 19, 2025
While endurance running is widely celebrated for its health benefits, a trailblazing study led by Tim Cannon, MD, Sheridan Director of the Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova Schar Cancer, reveals a surprising link to colon cancer risk. Featured in Runner’s World, the research opens important conversations around screening…
Read MoreGroundbreaking Inova study finds potential link between long-distance running and colon cancer
Fairfax, VA – A groundbreaking new study led by Tim Cannon, MD, Sheridan Director, Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program at Inova Schar Cancer, has revealed a potential link between extreme endurance exercise and increased risk of advanced colon cancer in younger adults, raising new questions about screening for high-performance athletes.…
Read MoreEndurance Sports and Colorectal Cancer: Is There a Connection?
Timothy L. Cannon, MD, is board certified in medical oncology, hematology and internal medicine. He serves as the Sheridan Director, Molecular Tumor Board and Co-Director of the Gastrointestinal Cancer Program. After treating three ultramarathoners who had developed colorectal cancer in recent years, I had a suspicion: This could be more than a coincidence. I found…
Read MoreJustice Ruth Bader Ginsburg Treated Again For Cancer, NPR
Immunotherapy: Cancer Care Gets Customized
Timothy L. Cannon, MD, is board certified in medical oncology and hematology, and has a special interest in managing gastrointestinal cancers. Dr. Cannon is the clinical director and moderator of Inova’s weekly molecular tumor board, which matches patients with targeted therapies based on molecular diagnostics. Tiffani A. DeMarco, MS, CGC, is a board-certified…
Read More